[PDF] Top 20 Supplementary material: Plasma Trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 diabetes

... Supplementary material Plasma Trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 ... Voir le document complet

... levels and patients’ characteristics (see Table ...observed in the replication compared to the discovery step could also be due to the well- known winner curse effect 45,46 ...miRNAs with ... Voir le document complet

... SR and enalapril treatment were well tolerated in this study, and no new adverse events ...adverse events, in that cough is not usually related to diuretic use, and ... Voir le document complet

... role in the improvement of either CV [130] or renal [131] outcomes. In patients with T2DM at high CV risk recruited for the Empagliflozin Cardiovascular Outcome Event Trial ... Voir le document complet

... advances in molecular biology and the continued identifi cation of increasingly more molecules involved in the insulin signaling cascade, the molecular mechanism (or mechanisms) that ... Voir le document complet

... Division of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU Sart Tilman, B-4000 Liège, ...independent cardiovascular risk factor in patients ... Voir le document complet

... loss in overweight or obese type 2 diabetes patients improves lipid profile, blood pressure, and diabetes ...associated with a reduced mortality risk ... Voir le document complet

... Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational ... Voir le document complet

... values in this range reached approximately ...bound of HbA 1c for enrollment was to be reset at ≥7.0% for the remainder of the ...enrolled. Patients were excluded if they had received a ... Voir le document complet

... discovery of insulin, insulin therapy is still controversial in the management of patients with type 2 diabetes so that the questions why, when and how to ... Voir le document complet

... Society of Cardiology Young Investigator research grant, and has received research support from Roche Diagnostics, Boeringer-Ingelheim, Takeda, Akcea, and the Canadian Cardiovascular Society ... Voir le document complet

... eradication with IFN-based therapy has a positive effect on the risk for IR ...HCV-infected patients treated with pegylated IFN + RBV and assessed the development of IR, defined ... Voir le document complet

... number of strengths including size (high statistical power even after risk factor stratification), prospective design (reducing the risk of reverse causation bias), and inclusion ... Voir le document complet

... position with health behaviors and ...Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care ...on diabetes, pre-diabetes, and ... Voir le document complet

... effects and peripheral metabolic effects in adipose tissue, liver, skeletal muscle and pancreas ...[95,96]. In non-diabetic overweight/obese patients, rimonabant 20 mg, as compared to ... Voir le document complet

... variants and dietary wholegrain products [33], the gly- cemic index, glycemic load [34] and polyunsaturated fatty acids [35] when considering the risks of T2D and athero- genic ... Voir le document complet

... Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, Liège, ...analysis of the Diabetes Prevention Program (DPP) showed that ... Voir le document complet

... profiles in cells, and these changes may persist after return to normo- glycemic ...occur and participate in the acquisi- tion of a cancerous phenotype in these cancer ...skin, ... Voir le document complet

... exposure with increased mortality, with a dose-response relation in patients with type 2 ...results of earlier studies, an epidemiological study cannot show a ... Voir le document complet

... weight and waist circumference in a randomised clinical trial in overweight/obese patients with type 2 diabetes treated with metformin (65%) or sulfonylureas ... Voir le document complet